Search clinical trials for: Combination of varlilumab and nivolumab

Total 147530 results

Universitair Ziekenhuis Brussel

Completed

A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases (ipniv)

Stage IV Skin Melanoma | Stage IIIC Skin Melanoma

Belgium
Sanofi
Regeneron Pharmaceuticals

Completed

Sarilumab COVID-19

Corona Virus Infection

Italy, Japan, Israel, Argentina, Russian Federation, Germany, Spain, Brazil, Chile, Canada, France
Bristol-Myers Squibb

Recruiting

A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread (CheckMate-67T)

Clear Cell Renal Cell Carcinoma

Russian Federation, New Zealand, United States, Finland, France, Ireland, Italy, Turkey, Poland, Argentina, Brazil, Chile, Czechia, Mexico, Portugal, Romania, Spain
Bristol-Myers Squibb

Active, not recruiting

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

Advanced Solid Tumor

Canada, United States, Mexico
Parker Institute for Cancer Immunotherapy
Bristol-Myers Squibb

Completed

Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy

Melanoma

United States
AIO-Studien-gGmbH
Bristol-Myers Squibb

Completed

Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma (TITAN-RCC)

Carcinoma, Renal Cell | Clear-cell Metastatic Renal Cell Carcinoma

Spain, France, Italy, Germany, United Kingdom, Belgium, Czechia, Austria
Exelixis

Recruiting

Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002)

Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Metastatic Castration-resistant Prostate Cancer

United States, Poland, Spain, Switzerland, Austria, Australia, Belgium, Israel, Italy, New Zealand, France, Germany, United Kingdom
NEOS Surgery
Hospital Clinic of Barcelona; Complejo Hospitalario de Navarra; Universitätsklinikum...

Recruiting

RCT to Evaluate STERN FIX Device as a Sternal Stabilization System in Patients After Sternotomy (FIXTER-2)

Median Sternotomy

Spain, Germany
Kaohsiung Medical University Chung-Ho Memorial...
Ministry of Health and Welfare, Taiwan

Enrolling by invitation

Optimizing Care for Challenging People Living With HIV

HIV Infections | Adherence, Medication | Social Media

Taiwan
Dana-Farber Cancer Institute
Bristol-Myers Squibb

Recruiting

An Open-Label Phase II Study of Nivolumab in Adult Participants With Progessive/ Recurrent Meningioma

Meningiomas

United States
Namyi Gu

Unknown

Study of Metformin and S. Baicalensis Combination Therapy in Type 2 Diabetes Mellitus Patients

Diabetes Mellitus

Korea, Republic of
Memorial Sloan Kettering Cancer Center
IO Biotech

Recruiting

A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma

Melanoma

United States
TaiRx, Inc.

Recruiting

CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma | Advanced Cancer

Taiwan
YULISU
Ono Pharmaceutical Co. Ltd

Recruiting

Neoadjuvant Nivolumab for Upper Tract Urothelial Carcinoma

Upper Urinary Tract Urothelial Carcinoma

Taiwan
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC

Completed

A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Korea, Republic of, Taiwan, Canada, Italy, Japan, Portugal, Spain, United Kingdom
Stichting Hemato-Oncologie voor Volwassenen Nederland

Active, not recruiting

DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL (HO152)

Lymphoma, B-Cell | Non Hodgkin Lymphoma | High-grade B-cell Lymphoma | MYC Translocation | BCL-2 Translocation

Netherlands, Belgium
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (CheckMate73L)

Non-Small Cell Lung Cancer (NSCLC)

Russian Federation, United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Greece, Ireland, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Puerto Rico, Romania, Spain, Sweden, Swit... and more
Sheba Medical Center

Active, not recruiting

MILESTONE-CD -A Prospective Multiomic Inception Real -Life Study To Evaluate Predictors of Disease Outcomes & respoNse to Biologic Treatment in Crohn's Disease (MILESTONE-CD)

Crohn Disease of Intestine

Israel
Centre Leon Berard

Recruiting

Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype (RAR-Immune)

Sarcoma

France
Jason J. Luke, MD
Bristol-Myers Squibb; Agios Pharmaceuticals, Inc.

Completed

Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors

Glioma | Advanced Solid Tumor | IDH1 Mutation

United States
Chinese PLA General Hospital

Not yet recruiting

Nivolumab, S-1 Combined With Oxaliplatin Versus Nivolumab as Neoadjuvant Therapy in Advanced Gastric Cancer

Gastric Cancer | Chemotherapy Effect
The Netherlands Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC (Indi-Blade)

Bladder Cancer | Urothelial Carcinoma

Netherlands
Bristol-Myers Squibb

Completed

A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection (CheckMate-6GE)

Melanoma

United States, Australia, Belgium, Italy, Poland, Spain, United Kingdom
Bristol-Myers Squibb

Withdrawn

A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer

Melanoma | Urothelial Carcinoma

Germany, Spain
Presage Biosciences
Bristol-Myers Squibb; Celgene

Terminated

Intratumoral Microdosing of Motolimod in HNSCC

HNSCC

United States
Taiho Oncology, Inc.

Completed

A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC

Refractory Metastatic Colorectal Cancer

United States
Institut Claudius Regaud

Terminated

Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)

Melanoma

France
China Medical University Hospital

Recruiting

Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1

Hepatocellular Carcinoma

Taiwan
NYU Langone Health

Terminated

A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Melanoma

United States
Fujian Medical University

Active, not recruiting

The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer

Locally Advanced Gastric Cancer

China
Bayer
Bristol-Myers Squibb

Completed

Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)

Colorectal Cancer

United States
Nantes University Hospital
Bristol-Myers Squibb

Recruiting

Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients (Nivo-TIL)

Melanoma

France
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma

Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma | Fumarate Hydratase Deficient Renal Cell Carcinoma | Succinate Dehydrogenase Deficient Renal Cell Carcinoma | Collecting Duct Renal...

United States
Robert L. Ferris, MD, PhD
Bristol-Myers Squibb

Active, not recruiting

Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer

Oropharynx Squamous Cell Carcinoma | Carcinoma, Squamous Cell of Head and Neck

United States
Daiichi Sankyo, Inc.
Bristol-Myers Squibb

Terminated

Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer

Colorectal Neoplasm

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)

Melanoma

Argentina, United States, Australia, Austria, Belgium, Canada, Czechia, Finland, France, Greece, Hungary, Ireland, Italy, Japan, Korea, Republic of, Netherlands, Norway, Poland, Romania, South Africa, Spain, Sweden, Switzerland, Taiwan, United Kingdom
Gruppo Oncologico del Nord-Ovest

Completed

NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN (NIVACTOR)

Squamous Cell Carcinoma of Head and Neck

Italy
Ralph G Zinner
Bristol-Myers Squibb

Recruiting

Induction Chemo-Nivo in Unresectable Stage III NSCLC

Lung Cancer, Nonsmall Cell | Lung Cancer Stage III

United States
Raymond T. Chung, MD
Merck Sharp & Dohme LLC

Withdrawn

Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant

Hepatitis C | Cardiac Transplant Disorder

United States
Sheba Medical Center
Prof. Ronit Satchi-Fainaro, Director, Cancer Biology Research Center, Tel...

Recruiting

Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases (14)

Advanced Glioblastoma | MGMT-Unmethylated Glioblastoma | Metastatic Melanoma in the Central Nervous System

Israel
Assistance Publique - Hôpitaux de Paris

Recruiting

Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence (CAPTiRALL)

Acute Lymphoblastic Leukemia, in Relapse | B Acute Lymphoblastic Leukemia

France
Tempest Therapeutics

Completed

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Sarcoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Pancreatic Cancer | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Non-small Cell Lung Cancer | Urothelial Carcinoma | GastroEsophageal Cancer | Triple-Negative Breast Cancer | Metastatic Castration Resistant Prostate...

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (CheckMate 648)

Various Advanced Cancer

United States, Japan, Argentina, Australia, Austria, Brazil, Canada, Chile, China, Colombia, Czechia, Denmark, France, Hong Kong, Italy, Korea, Republic of, Mexico, Peru, Poland, Portugal, Romania, Russian Federation, Singapore, Spain, ... and more
Instituto de Investigación Marqués de Valdecilla

Unknown

Effect of Sarilumab on Atherosclerotic Disease Assessed by PET/CET in Patients With RA (SARIPET) (SARIPET)

Rheumatoid Arthritis | Atherosclerosis
Bristol-Myers Squibb

Completed

Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma (CheckMate 066)

Melanoma

Canada, Australia, Germany, Italy, Poland, France, Denmark, Argentina, Chile, Spain, Norway, Israel, Sweden, Mexico, Greece, Finland
Bristol-Myers Squibb

Recruiting

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127)

Melanoma

United States, Canada, Switzerland, Italy, Spain, Australia, France, Belgium, Finland, Israel, Germany, Sweden, Argentina, Brazil, Colombia, Mexico, Norway, Chile, United Kingdom, Austria, Poland, Czechia
Gritstone bio, Inc.
Bristol-Myers Squibb

Completed

A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens

Colorectal Cancer | Pancreatic Cancer | Non-Small Cell Lung Cancer | Solid Tumor | Shared Neoantigen-Positive Solid Tumors

United States
Bristol-Myers Squibb

No longer available

Expanded Access for Fixed-Dose Combination of Nivolumab Plus Relatlimab
Fujian Cancer Hospital

Withdrawn

Study of FMT Combined With Nivolumab in Gastric Cancer

Gastric Adenocarcinoma | Esophagus Adenocarcinoma | Esophagogastric Junction Adenocarcinoma

China
St. Petersburg State Pavlov Medical University

Completed

Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma (Nivo40)

Hodgkin Lymphoma

Russian Federation

Search clinical trials for: Combination of varlilumab and nivolumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations